Maternal Health

Monitoring for early identification of conditions that affect maternal and fetal health, including gestational diabetes, preeclampsia, and nutrients necessary for fetal neural development

LEARN MORE

Intelligent biosensors that power the future of healthcare

Predict changes. Intervene earlier. Prevent progression.

PercuSense’s continuous multi-analyte sensor system combines monitoring of multiple biosensors with knowledge of how diseases and illness progress to intelligently and proactively recommend treatment.

HOW IT WORKS

ABOUT US

Why PercuSense?

High Performance, Low-Cost

Calibration-free performance that CGM users are accustomed to, in a more affordable package

Measure Multiple Parameters in a Single Sensor

Glucose, lactate, oxygen, ketones, and more. A combination of measurements tailored to each disease state

Added Features without
Added Size

The information doubles, but the size doesn't.

Multi-parameter monitoring in a small area

Unique Innovation Protected with Patents

Robust intellectual property with multiple granted worldwide patents protecting novel ideas

Latest News

PercuSense Will Present at the Chemical & Biological Defense S&T Conference

November 8, 2024

PercuSense’s CEO, Brian Kannard, will be at the Chemical and Biological Defense Science and Technology (CBD S&T) conference giving an oral presentation to unveil exciting new data from the ChemWatch system. For the first time, we will present in vivo data demonstrating the sensor’s ability to detect simulated warfare agents.

PercuSense to Present at the 2024 Diabetes Technology Meeting in San Francisco

October 10, 2024

PercuSense will present at the 24th Annual Diabetes Technology Meeting on October 15th-17th. PercuSense will present a poster titled “Feasibility of Multi-Metabolic Continuous Monitoring: Atlas HealthTM, A Roadmap to Improving Metabolic Health” covering recent advancements in the glucose and lactate sensor and the promise of lactate as a key metabolic analyte.

Groundbreaking Multi-Analyte Glucose and Lactate Sensor First-in-Human Results

August 19, 2024

PercuSense Inc. is thrilled to share the results of a groundbreaking first-in-human study, a clinical evaluation of the first-ever percutaneous multi-analyte CGM[+] system. PercuSense’s novel device combines glucose and lactate sensors on a single probe to provide simultaneous, continuous measurements of both analytes.